accelerated pre-treatment evaluation for hcv infected persons who inject drugs

Conditions: Hepatitis C; Intravenous Drug Users

Summary: persons who inject drugs (pwid) are overrepresented among hepatitis c infected patients, but underrepresented among those who are treated, despite many studies showing that treatment is feasible and effective in this population. the hepatitis c diagnosis and pre-treatment evaluation are multistep processes. every step is a potential occasion for disengagement and loss to follow-up. this is especially true with hard-to-reach populations such as pwid in whom competing needs are numerous and psychosocial situation can change rapidly. by using new technologies that can quickly provide clinical results, like xpert hcv viral load (cepheid) and transient elastography (fibroscan), a provider could determine if a patient needs treatment rapidly or not on the day of the initial visit. the aim of this study is to explore whether an accelerated pre-treatment evaluation can result in an improved linkage-to-care (defined as linkage to health care, addiction or social services) and, eventually, linkage-to-treatment among pwid.

this is a non-randomized, open-label study that aims to include hcv-infected patients who inject drugs and who do not know their treatment eligibility status. a total of 200 patients will be evaluated using our rapid evaluation protocol, which will include basic blood tests, viral load measurement using cepheid's xpert® hcv viral load technique (which will be controlled at the same time by cobas® ampliprep/ cobas® taqman® hcv quantitative test, version 2.0 (roche), available at the chum and approved by health canada), a liver fibrosis assessment and hcv genotyping. the results of the basic tests, viral load tests and fibroscan® test will be available on the same day as the patient's visit and will allow the investigator to determine straightaway whether or not the patient is treatable based on the ramq's reimbursement criteria at the time of the study. if the patient is treatable, once the genotype result has been obtained, the most appropriate treatment for their medical condition, degree of liver fibrosis and genotype will be prescribed. there will be no other visits between the initial visit and the treatment initiation visit. the patient will be given an appointment for the treatment initiation visit once the medication has been approved by the ramq or the patient's private insurer. the patient will be seen again at weeks 2 and 4 of treatment, at the end of treatment (usually week 12), then 12, 24 and 36 weeks post-treatment. if the patient is not treatable, he/she will be referred to the chum addiction medicine clinic or the uhress (if hiv-coinfected status) for management, which will include longitudinal follow-up of his hcv and substance abuse. the patient will be seen again at 6 months and 1 year to determine whether or not there has been linkage-to-care, initiation of opioid substitution therapy if indicated and if the patient has reduced his injection drug use. if an untreatable patient becomes treatable during follow-up, treatment will be offered. at the same time, we will review the records of patients seen at the chum addiction medicine clinic between october 2014 and june 2016 who meet the inclusion criteria for the study cohort and the ramq's treatment eligibility criteria. this cohort will be used as an historical cohort to determine the rate of linkage to treatment with the standard pre-treatment evaluation protocol.

Eligibility criteria:
inclusion criteria: * person who inject drugs, defined as having injected in the past year * able to give an informed consent * unknown treatment eligibility status exclusion criteria: * patients actively engaged in hcv follow up * patients visibly intoxicated at initial study visit * pregnant or breastfeeding women * pacemaker.